Thomas Jaki
Thomas Jaki
Programme Leader at MRC Biostatistics Unit and Professor of Statistics at Lancaster University
Verified email at lancaster.ac.uk - Homepage
Title
Cited by
Cited by
Year
A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19
B Cao, Y Wang, D Wen, W Liu, J Wang, G Fan, L Ruan, B Song, Y Cai, ...
New England Journal of Medicine, 2020
17252020
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Y Wang, D Zhang, G Du, R Du, J Zhao, Y Jin, S Fu, L Gao, Z Cheng, Q Lu, ...
The Lancet, 2020
5312020
A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection
D Magirr, T Jaki, J Whitehead
Biometrika 99 (2), 494-501, 2012
1072012
Adaptive designs in clinical trials: why use them, and how to run and report them
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16 (1), 1-15, 2018
1062018
Probabilistic relabelling strategies for the label switching problem in Bayesian mixture models
M Sperrin, T Jaki, E Wit
Statistics and Computing 20 (3), 357-366, 2010
1012010
Assessing differential effects: Applying regression mixture models to identify variations in the influence of family resources on academic achievement.
ML Van Horn, T Jaki, K Masyn, SL Ramey, JA Smith, S Antaramian
Developmental psychology 45 (5), 1298, 2009
972009
Optimal design of multi‐arm multi‐stage trials
J Wason, T Jaki
Statistics in Medicine 31 (30), 4269-4279, 2012
792012
Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report
P Horby, WS Lim, JR Emberson, M Mafham, JL Bell, L Linsell, N Staplin, ...
The New England Journal of Medicine, 0
69*
Some recommendations for multi-arm multi-stage trials
J Wason, D Magirr, M Law, T Jaki
Statistical methods in medical research 25 (2), 716-727, 2016
592016
Estimation of pharmacokinetic parameters with the R package PK
T Jaki, MJ Wolfsegger
Pharmaceutical Statistics, 2011
512011
Differential effects of parental controls on adolescent substance use: For whom is the family most important?
AA Fagan, ML Van Horn, JD Hawkins, T Jaki
Journal of quantitative criminology 29 (3), 347-368, 2013
492013
Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report
P Horby, WS Lim, J Emberson, M Mafham, J Bell, L Linsell, N Staplin, ...
MedRxiv, 2020
462020
Principles of dose finding studies in cancer: a comparison of trial designs
T Jaki, S Clive, CJ Weir
Cancer chemotherapy and pharmacology 71 (5), 1107-1114, 2013
432013
A review of statistical updating methods for clinical prediction models
TL Su, T Jaki, GL Hickey, I Buchan, M Sperrin
Statistical methods in medical research 27 (1), 185-197, 2018
392018
Uptake of novel statistical methods for early-phase clinical studies in the UK public sector
T Jaki
Clinical Trials 10 (2), 344-346, 2013
382013
Using multilevel mixtures to evaluate intervention effects in group randomized trials
ML Van Horn, AA Fagan, T Jaki, EC Brown, JD Hawkins, MW Arthur, ...
Multivariate Behavioral Research 43 (2), 289-326, 2008
342008
A Bayesian adaptive design for clinical trials in rare diseases
SF Williamson, P Jacko, SS Villar, T Jaki
Computational Statistics & Data Analysis 113, 136-153, 2017
332017
One‐and two‐stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint
J Whitehead, T Jaki
Statistics in medicine 28 (5), 828-847, 2009
332009
Modeling predictors of latent classes in regression mixture models
M Kim, J Vermunt, Z Bakk, T Jaki, ML Van Horn
Structural Equation Modeling: A Multidisciplinary Journal 23 (4), 601-614, 2016
312016
Flexible sequential designs for multi‐arm clinical trials
D Magirr, N Stallard, T Jaki
Statistics in medicine 33 (19), 3269-3279, 2014
282014
The system can't perform the operation now. Try again later.
Articles 1–20